InvestorsObserver is giving Fate Therapeutics Inc (FATE) an Analyst Rating Rank of 20, meaning FATE is ranked higher by analysts than 20% of stocks. The average price target for FATE is $7.031 and analyst’s rate the stock as a Buy.
Wall Street analysts are rating FATE a Buy today. Find out what this means to you and get the rest of the rankings on FATE!
Analysts know the inner workings of the companies they follow better than anyone but the companies’ management. You can learn a lot about a company from studying the financial statements, but analysts ask questions on conference calls and understand the intricacies of each of the businesses they cover. Analysts understand how bad weather in one part of the world can disrupt supply chains, or disrupt shopping patterns. This lets traders make decisions before a quarterly report that could be worse than expected.
InvestorsObserver aggregates the ratings of all the analysts covering a given stock, takes the average of those ratings and then percentile ranks the averages. That provides a level of granularity that is significantly better than just the three levels provided by traditional buy/hold/sell ratings.
What's Happening With Fate Therapeutics Inc Stock Today?
Fate Therapeutics Inc (FATE) stock is trading at $2.64 as of 12:54 PM on Monday, Nov 20, a rise of $0.20, or 8.44% from the previous closing price of $2.43. The stock has traded between $2.38 and $2.70 so far today. Volume today is less active than usual. So far 855,321 shares have traded compared to average volume of 1,795,787 shares.
Click Here to get the full Stock Report for Fate Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
